Recently, osimertinib, a third-generation EGFR-TKI has been approved in multiple countries, including Canada, for the treatment of patients with locally advanced or metastatic EGFRm NSCLC in the first setting based on the superiority of osimertinib compared to first-generation EGFR-TKI [20]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.